ONCAlert | Upfront Therapy for mRCC

The Journal of Targeted Therapies in Cancer
March 2012

Clinical Articles

Full PDF Version of OncologyLive Targeted Therapy News from March 2012

Colorectal Tumor Marker: Molecular Evaluation Sheds Light on Negative Lymph Node Status

Changing Paradigms for NSCLC in Personalized Therapy Era

Biomarker Identifies Patients With Advanced Lung Cancer Who Will Gain Most From Add-On Cetuximab

Prostate Cancer Armamentarium Expanding

Emerging Biomarker Science Presents Practical Questions

PARP Inhibition Explored in Triple-Negative Breast Cancer

Clinicians Face Challenges Integrating New Therapeutics

Trial Shows Denosumab Delays Development of Bone Metastasis in Hormone-Resistant Prostate Cancer

New Assays Open Window in Evaluating Leukemia Types

Using Molecular Markers in AML for Prediction, Treatment, and Monitoring

Predictive Markers Needed for Adjuvant Chemotherapy

Hospitals for Vulnerable Patients Less Likely to Provide Optimal Lung Cancer Care

FDA Approves Axitinib for Advanced Kidney Cancer Patients

Two New Options Represent Breakthroughs

Hair Professionals Often Check Customers for Worrisome Skin Lesions

Better Communication of Complex Medical Information Needed

Some Follicular Lymphoma Patients May Benefit From Treatment Delay

The Hope and Challenges of Personalized Medicine

Targeted Therapies Trials in Progress

NICEâ€™s Reluctance to Back Yervoy Turns on Cost-Benefit Perceptions

Pierre Hainaut, PhD: Awakening the â€œGuardian of the Genomeâ€

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.